首页> 外文期刊>Stem cells translational medicine. >A Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction
【24h】

A Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction

机译:间充质干细胞和角膜缘上皮干细胞对眼表重建的治疗潜力的比较研究

获取原文
           

摘要

Stem cell-based therapy has become an attractive and promising approach for the treatment of severe injuries or thus-far incurable diseases. However, the use of stem cells is often limited by a shortage of available tissue-specific stem cells; therefore, other sources of stem cells are being investigated and tested. In this respect, mesenchymal stromal/stem cells (MSCs) have proven to be a promising stem cell type. In the present study, we prepared MSCs from bone marrow (BM-MSCs) or adipose tissue (Ad-MSCs) as well as limbal epithelial stem cells (LSCs), and their growth, differentiation, and secretory properties were compared. The cells were grown on nanofiber scaffolds and transferred onto the alkali-injured eye in a rabbit model, and their therapeutic potential was characterized. We found that BM-MSCs and tissue-specific LSCs had similar therapeutic effects. Clinical characterization of the healing process, as well as the evaluation of corneal thickness, re-epithelialization, neovascularization, and the suppression of a local inflammatory reaction, were comparable in the BM-MSC- and LSC-treated eyes, but results were significantly better than in injured, untreated eyes or in eyes treated with a nanofiber scaffold alone or with a nanofiber scaffold seeded with Ad-MSCs. Taken together, the results show that BM-MSCs' therapeutic effect on healing of injured corneal surface is comparable to that of tissue-specific LSCs. We suggest that BM-MSCs can be used for ocular surface regeneration in cases when autologous LSCs are absent or difficult to obtain. SignificanceDamage of ocular surface represents one of the most common causes of impaired vision or even blindness. Cell therapy, based on transplantation of stem cells, is an optimal treatment. However, if limbal stem cells (LSCs) are not available, other sources of stem cells are tested. Mesenchymal stem cells (MSCs) are a convenient type of cell for stem cell therapy. The therapeutic potential of LSCs and MSCs was compared in an experimental model of corneal injury, and healing was observed following chemical injury. MSCs and tissue-specific LSCs had similar therapeutic effects. The results suggest that bone marrow-derived MSCs can be used for ocular surface regeneration in cases when autologous LSCs are absent or difficult to obtain.
机译:基于干细胞的疗法已成为治疗严重伤害或迄今无法治愈的疾病的一种有吸引力且有希望的方法。但是,干细胞的使用通常受到可用组织特异性干细胞的缺乏的限制。因此,正在研究和测试其他干细胞来源。在这方面,间充质基质/干细胞(MSC)已被证明是一种有前途的干细胞类型。在本研究中,我们从骨髓(BM-MSC)或脂肪组织(Ad-MSC)以及角膜缘上皮干细胞(LSCs)中制备了MSC,并比较了它们的生长,分化和分泌特性。这些细胞在纳米纤维支架上生长,并转移到兔子模型中的碱损伤眼中,并对其治疗潜力进行了表征。我们发现,BM-MSC和组织特异性LSC具有相似的治疗效果。在BM-MSC和LSC治疗的眼睛中,其愈合过程的临床表征以及角膜厚度,重新上皮形成,新血管形成和局部炎症反应抑制的评估均具有可比性,但结果明显更好比受伤的,未经治疗的眼睛或仅用纳米纤维支架或接种Ad-MSC的纳米纤维支架治疗的眼睛要高。两者合计,结果表明,BM-MSC对角膜受损表面愈合的治疗效果与组织特异性LSC相当。我们建议,当自体LSC缺失或难以获得时,BM-MSC可用于眼表再生。重要性眼表损伤是导致视力受损甚至失明的最常见原因之一。基于干细胞移植的细胞疗法是一种最佳疗法。但是,如果没有角膜缘干细胞(LSC),则将测试其他来源的干细胞。间充质干细胞(MSC)是用于干细胞治疗的一种方便的细胞类型。在角膜损伤的实验模型中比较了LSC和MSC的治疗潜力,并观察到化学损伤后的愈合情况。 MSC和组织特异性LSC具有相似的治疗效果。结果表明,在缺乏或难以获得自体LSC的情况下,骨髓来源的MSC可用于眼表再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号